Jefferies Resumes BioScrip (BIOS) at Buy

November 8, 2016 7:22 AM EST
Get Alerts BIOS Hot Sheet
Price: $1.21 +6.14%

Rating Summary:
    6 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade BIOS Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Jefferies resumes coverage on BioScrip (NASDAQ: BIOS) with a Buy rating and a price target of $2.50.

Analyst Brian Tanquilut commented, "We were surprised by BIOS's disappointing Q3 and the resulting guidance cut, and recognize that it further dents the company's already-weak credibility with investors. That said, we believe the issues were solely associated with BIOS's old regime and that new mgmt. has already put in place measures to significantly reduce costs and drive targeted growth in core therapies."

For an analyst ratings summary and ratings history on BioScrip click here. For more ratings news on BioScrip click here.

Shares of BioScrip closed at $2.61 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co

Add Your Comment